Assisted reproductive technology using oocytes derived from iPS cells

Dioseve specializes in innovative biotechnological solutions, particularly through its proprietary technology known as DIOLs (Directly Induced Oocyte-like cells). This technology enables the rapid generation of oocyte-like cells from induced pluripotent stem cells (iPS cells), facilitating significant advancements in reproductive health. By harnessing this method, Dioseve aims to address critical challenges in infertility treatments and the investigation of genetic diseases, providing novel solutions where traditional methods have fallen short.

The company is committed to the social implementation of its groundbreaking technologies, actively seeking collaboration with individuals who share a vision for tackling various accessible challenges. Dioseve's focus on innovation and its dedication to advancing scientific understanding underscore its mission to contribute meaningfully to the fields of reproductive medicine and genetic research, ultimately enhancing the quality of life for individuals facing these complex issues.

Japan

Dioseve Inc. Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost.

Genetic Diseases

Urogenital Diseases

1-17-8 Shinkiba, Koto-ku, Tokyo 136-0082, Japan Mitsui Link Lab Shinkiba 2 Room 223

Dioseve

Company Details